-
12 hours ago | 
biopharminternational.com | Patrick Lavery
Biotechnology company Repertoire Immune Medicines announced on April 23, 2025 that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, for the discovery and development of innovative, T cell-targeted therapies to treat an autoimmune disease (1). Repertoire’s DECODE platform will be deployed to discover novel therapeutic targets across a large antigenic space, according to a press release (1).
-
1 day ago | 
biopharminternational.com | Patrick Lavery
Editor's note: this story was originally published on PharmTech.com. On April 22, 2025, Roche announced a new $50 billion investment into increasing its footprint in the United States between now and 2030, specifically for pharmaceutical manufacturing and diagnostics. The investment is expected to create more than 12,000 jobs, which includes approximately 6500 in construction and 1000 jobs at new and expanded facilities, according to a company press release (1).
-
3 days ago | 
biopharminternational.com | Patrick Lavery
GSK announced on April 17, 2025 that its belantamab mafodotin, an antibody-drug conjugate (ADC) that comprises a humanized B cell maturation antigen (BCMA) monoclonal antibody (mAb) conjugated to the cytotoxic agent auristatin F via a non-cleavable linker, has been authorized by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) (1).
-
6 days ago | 
biopharminternational.com | Patrick Lavery
Thermo Fisher Scientific has opened a new Advanced Therapies Collaboration Center, which the company abbreviates as ATxCC (1). The 6000-square-foot facility is in Carlsbad, Calif., which is situated in the greater San Diego area. Thermo Fisher announced the grand opening on April 17, 2025.
-
6 days ago | 
biopharminternational.com | Patrick Lavery
The United States Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has recommended Bavarian Nordic’s recombinant vaccine for the prevention of disease caused by chikungunya virus (1). Bavarian Nordic, which is based in Denmark, reported the recommendation of the virus-like particle (VLP)-based, single-dose injection (brand name Vimkunya) on April 16, 2025.
-
1 week ago | 
biopharminternational.com | Patrick Lavery
On April 10, 2025, FDA said it would be taking steps to replace animal testing in development of monoclonal antibody (mAb) therapies and other drugs with “human-relevant” methods the agency said are more effective (1). Aside from the clear goal of reducing animal experimentation, FDA also said it expects the shift in policy to improve drug safety, accelerate the evaluation process, and lower both R&D costs and, ultimately, drug prices.
-
2 weeks ago | 
biopharminternational.com | Patrick Lavery
As Pharmaceutical Technology® Group was busy networking with industry leaders at INTERPHEX 2025 in New York City on April 2, United States President Donald Trump scheduled the announcement of what he called “Liberation Day” with a 10% baseline tariff on imported goods from most other countries in the world, effective April 5 (1).
-
2 weeks ago | 
biopharminternational.com | Patrick Lavery
When single-use technologies began to be adopted, the attitude in the bio/pharmaceutical industry was a “wild wild West,” says Todd Andrews, global director of Applications and Business Development for CPC’s Biopharma business. Andrews spoke exclusively with Pharmaceutical Technology® Group at INTERPHEX 2025 in New York City.
-
2 weeks ago | 
biopharminternational.com | Patrick Lavery |Feliza Mirasol
Editor's note: this interview was originally published on PharmTech.com. Michael Franco, global sales director at PSG Biotech, sat down with the PharmTech Group at INTERPHEX 2025 and discussed how recent advancements in pharmaceutical flow sensor technology primarily focus on improving measurement accuracy as drug production becomes more expensive and precise. He points out a key development, which is the enhancement of Coriolis single-use flow meters.
-
2 weeks ago | 
biopharminternational.com | Patrick Lavery |Feliza Mirasol
Editor's note: this interview was originally published on PharmTech.com. Supply-chain disruptions caused by the COVID-19 pandemic led to extended lead times, sometimes exceeding a year, which significantly impacts biopharmaceutical manufacturing and patient access to therapies, according to Nicole Hunter, head of Global WMArchitect at Watson-Marlow Fluid Technology Solutions (WMFTS).
